Checking CUE unusual options activity helps you spot when traders are making outsized bets on Cue Biopharma Inc before the broader market catches on. Unusual activity flags contracts trading at multiples of their average daily volume, often signaling informed money positioning ahead of a catalyst. Use our scanner to monitor CUE unusual options activity today and surface the prints that deserve a second look.
Unusual options flow typically means volume vastly exceeds open interest at a given strike, or total contract volume on a name spikes well above its norm. Watching CUE unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CUE unusual options volume across calls and puts helps you separate hedging from genuinely speculative positioning, especially valuable around earnings, product launches, and macro events.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases.
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →